The new phase two CELIA trial was funded by Biogen, which is developing the drug with Ionis Pharmaceuticals.
It enrolled 416 patients with early Alzheimer’s disease across multiple centres worldwide.
Researchers tested three different doses of the jab against a placebo, with the strongest results found among 60 patients given the lowest dose of 60mg every six months.
